Ju Youn Kim, Ph.D., from the CTSC at Weill Cornell Medicine has been selected through a national competition by the National Institutes of Health’s National Center for Advancing Translational Sciences to partner with Eli Lilly in a novel pilot program—the NCATS-Eli Lilly Scholars Externship Program.
Dr. Kim began her three month externship at Eli Lilly earlier this month. At Lilly, Dr. Kim is working with a research mentor in Lilly’s department of Global Regulatory Affairs (GRA), Dr. Daniel Brady, on a project within a neuroscience drug development team to advance a new chemical or biological entity through the earliest phase of drug development. The project will provide her with an opportunity to develop a regulatory strategy and regulatory filings while working within a medical team developing the study protocol(s) and executing the clinical study(s).
Dr. Kim graduated from the University of Washington, Seattle, WA in 2005 with a B.S. in Biochemistry and molecular biology. She attended the Sackler Institute of Graduate Biomedical Sciences at NYU School of Medicine for her doctorate degree in Cell and Molecular Biology, with her thesis focusing on virology and the herpes simplex virus type I (HSV-1) in peripheral neurons. Her thesis work was primarily centered on finding more effective treatments and potential cure for HSV-1. She is currently at Weill Cornell Medical College as postdoctoral research associate working in Dr. Samie Jaffrey’s laboratory, one of the world-wide leaders in the analysis of local translation. Her current goal is to study the relationship between local translation in primary neurons and maintenance of HSV-1 in latency using the powerful in vitro model that she developed as a graduate student. This project strategically combines her expertise in HSV-1 and with her current laboratory’s expertise in mRNA translation in neurons.
The NCATS Lilly Externship Program supports the training and education of participants in techniques and principles needed to pursue research in one of the world’s premier pharmaceutical companies. The primary objective of the externship program is to enhance scholars’ core competencies in clinical trial design, clinical pharmacology, toxicology and other areas critical to the drug development process.
For more information about Weill Cornell Medicine’s research, visit weillcornell.org. To learn more about the research and work of the CTSC at Weill Cornell, visit weill.cornell.edu/ctsc.